Listed

Ocean Biomedical, Inc.: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on May 24, 2023 and accepted by EDGAR at May 24, 2023, 12:26 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2023-01-01 to 2023-03-31$393.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-01-01 to 2023-03-31−$5.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-01-01 to 2023-03-31$883.5kus-gaap:InterestExpense
Net income3 months2023-01-01 to 2023-03-31−$67.4mus-gaap:NetIncomeLoss
Basic EPS3 months2023-01-01 to 2023-03-31−$2.72us-gaap:EarningsPerShareBasic
Operating cash flow3 months2023-01-01 to 2023-03-31−$2.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2023-03-31$306.0kus-gaap:Cash
Current assetsAt period end2023-03-31$306.0kus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$25.0mus-gaap:Assets
Current liabilitiesAt period end2023-03-31$23.4mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2023-03-31$1.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-23-018924. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.